Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis

Detalhes bibliográficos
Autor(a) principal: Mercer, Louise K.
Data de Publicação: 2017
Outros Autores: Regierer, Anne C., Mariette, Xavier, Dixon, William G., Baecklund, Eva, Hellgren, Karin, Dreyer, Lene, Hetland, Merete Lund, Cordtz, Rene, Hyrich, Kimme, Strangfeld, Anja, Zink, Angela, Canhão, Helena, Victoria Hernandez, M., Tubach, Florence, Gottenberg, Jacques-Eric, Morel, Jacques, Zavada, Jakub, Iannone, Florenzo, Askling, Johan, Listing, Joachim
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10362/149317
Resumo: Funding: Individual registries had entered into agreements with pharmaceutical companies (AbbVie, BMS, Hospira, MSD, Pfizer, Roche, UCB, Samsung and Eli Lilly). The pharmaceutical companies funding these registers were, however, not involved in the planning of the project, the statistical analyses, the interpretation of the results or the decision to publish.
id RCAP_07af8401644050d9283e85db10d6adc5
oai_identifier_str oai:run.unl.pt:10362/149317
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritisa European registries collaborative projectepidemiologyrheumatoid arthritisanti-TNFDMARDs(biologic)Funding: Individual registries had entered into agreements with pharmaceutical companies (AbbVie, BMS, Hospira, MSD, Pfizer, Roche, UCB, Samsung and Eli Lilly). The pharmaceutical companies funding these registers were, however, not involved in the planning of the project, the statistical analyses, the interpretation of the results or the decision to publish.BACKGROUND: Lymphomas comprise a heterogeneous group of malignant diseases with highly variable prognosis. Rheumatoid arthritis (RA) is associated with a twofold increased risk of both Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). It is unknown whether treatment with biologic disease-modifying antirheumatic drugs (bDMARDs) affect the risk of specific lymphoma subtypes. METHODS: Patients never exposed to (bionaïve) or ever treated with bDMARDs from 12 European biologic registers were followed prospectively for the occurrence of first ever histologically confirmed lymphoma. Patients were considered exposed to a bDMARD after having received the first dose. Lymphomas were attributed to the most recently received bDMARD. RESULTS: Among 124 997 patients (mean age 59 years; 73.7% female), 533 lymphomas were reported. Of these, 9.5% were HL, 83.8% B-cell NHL and 6.8% T-cell NHL. No cases of hepatosplenic T-cell lymphoma were observed. Diffuse large B-cell lymphoma (DLBCL) was the most frequent B-cell NHL subtype (55.8% of all B-cell NHLs). The subtype distributions were similar between bionaïve patients and those treated with tumour necrosis factor inhibitors (TNFi). For other bDMARDs, the numbers of cases were too small to draw any conclusions. Patients with RA developed more DLBCLs and less chronic lymphocytic leukaemia compared with the general population. CONCLUSION: This large collaborative analysis of European registries has successfully collated subtype information on 533 lymphomas. While the subtype distribution differs between RA and the general population, there was no evidence of any modification of the distribution of lymphoma subtypes in patients with RA treated with TNFi compared with bionaïve patients. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)Centro de Estudos de Doenças Crónicas (CEDOC)Escola Nacional de Saúde Pública (ENSP)RUNMercer, Louise K.Regierer, Anne C.Mariette, XavierDixon, William G.Baecklund, EvaHellgren, KarinDreyer, LeneHetland, Merete LundCordtz, ReneHyrich, KimmeStrangfeld, AnjaZink, AngelaCanhão, HelenaVictoria Hernandez, M.Tubach, FlorenceGottenberg, Jacques-EricMorel, JacquesZavada, JakubIannone, FlorenzoAskling, JohanListing, Joachim2023-02-16T22:13:57Z2017-122017-12-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article6application/pdfhttp://hdl.handle.net/10362/149317eng0003-4967PURE: 3395748https://doi.org/10.1136/annrheumdis-2017-211623info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-11T05:31:16Zoai:run.unl.pt:10362/149317Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:53:43.144240Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis
a European registries collaborative project
title Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis
spellingShingle Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis
Mercer, Louise K.
epidemiology
rheumatoid arthritis
anti-TNF
DMARDs(biologic)
title_short Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis
title_full Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis
title_fullStr Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis
title_full_unstemmed Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis
title_sort Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis
author Mercer, Louise K.
author_facet Mercer, Louise K.
Regierer, Anne C.
Mariette, Xavier
Dixon, William G.
Baecklund, Eva
Hellgren, Karin
Dreyer, Lene
Hetland, Merete Lund
Cordtz, Rene
Hyrich, Kimme
Strangfeld, Anja
Zink, Angela
Canhão, Helena
Victoria Hernandez, M.
Tubach, Florence
Gottenberg, Jacques-Eric
Morel, Jacques
Zavada, Jakub
Iannone, Florenzo
Askling, Johan
Listing, Joachim
author_role author
author2 Regierer, Anne C.
Mariette, Xavier
Dixon, William G.
Baecklund, Eva
Hellgren, Karin
Dreyer, Lene
Hetland, Merete Lund
Cordtz, Rene
Hyrich, Kimme
Strangfeld, Anja
Zink, Angela
Canhão, Helena
Victoria Hernandez, M.
Tubach, Florence
Gottenberg, Jacques-Eric
Morel, Jacques
Zavada, Jakub
Iannone, Florenzo
Askling, Johan
Listing, Joachim
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
Centro de Estudos de Doenças Crónicas (CEDOC)
Escola Nacional de Saúde Pública (ENSP)
RUN
dc.contributor.author.fl_str_mv Mercer, Louise K.
Regierer, Anne C.
Mariette, Xavier
Dixon, William G.
Baecklund, Eva
Hellgren, Karin
Dreyer, Lene
Hetland, Merete Lund
Cordtz, Rene
Hyrich, Kimme
Strangfeld, Anja
Zink, Angela
Canhão, Helena
Victoria Hernandez, M.
Tubach, Florence
Gottenberg, Jacques-Eric
Morel, Jacques
Zavada, Jakub
Iannone, Florenzo
Askling, Johan
Listing, Joachim
dc.subject.por.fl_str_mv epidemiology
rheumatoid arthritis
anti-TNF
DMARDs(biologic)
topic epidemiology
rheumatoid arthritis
anti-TNF
DMARDs(biologic)
description Funding: Individual registries had entered into agreements with pharmaceutical companies (AbbVie, BMS, Hospira, MSD, Pfizer, Roche, UCB, Samsung and Eli Lilly). The pharmaceutical companies funding these registers were, however, not involved in the planning of the project, the statistical analyses, the interpretation of the results or the decision to publish.
publishDate 2017
dc.date.none.fl_str_mv 2017-12
2017-12-01T00:00:00Z
2023-02-16T22:13:57Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/149317
url http://hdl.handle.net/10362/149317
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 0003-4967
PURE: 3395748
https://doi.org/10.1136/annrheumdis-2017-211623
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 6
application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799138127300788224

Registros relacionados